Gilead Sciences and GlaxoSmithKline GSK) are going head-to-head in HIV treatments and they both have competing products that are expected to hit the market in the next few months, according to a Reuters article.
Gilead is favored with a bigger near-term win, as it builds on its strategy of combining three drugs to control the AIDS virus, while GSK is betting that its core drug is strong enough to work with only one other drug, the story says. There's a lot at stake for the two companies in the $27-billion-a-year HIV market.
In other GSK news, research and development head Patrick Vallance is rumored to be leaving the drugmaker to become the British government’s new chief scientific adviser, a source told Reuters.
Read the full story